Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials

Clinical Snapshot

Key Findings

• P Value: p=0.049 (ALIENTO every 2 weeks), p=0.024 (ARNASA every 4 weeks), p=0.068 (ARNASA every 2 weeks)

• Effect Size: Rate ratios: 0.85 (ALIENTO every 2 weeks), 0.82-0.93 (ARNASA both dosing regimens)

• Primary Outcome: Annualised rate of moderate or severe COPD exacerbations over 52 weeks

• Nnt Or Sensitivity: NNT not calculable from provided data; approximately 15-18% relative reduction in exacerbation rates

• Confidence Interval: 95% CI 0.72-1.00 (ALIENTO every 2 weeks), 0.70-0.98 (ARNASA every 4 weeks)

Clinical Application

Subcutaneous injection every 2-4 weeks feasible in specialist respiratory clinics, requires cold chain storage Would require TGA approval and PBS listing for accessibility; fits within COPD-X guidelines for patients with frequent exacerbations inadequately controlled on standard therapy Australian COPD patients with frequent exacerbations despite optimised inhaled therapy, regardless of eosinophil count

Abstract

BACKGROUND: Interleukin-33 and its receptor, ST2, are implicated in neutrophilic and eosinophilic inflammation during chronic obstructive pulmonary disease (COPD) exacerbations. We aimed to assess the efficacy and safety of astegolimab, an anti-ST2 human IgG2 monoclonal antibody, which were evaluated in two COPD pivotal trials. METHODS: In two randomised, double-blind, placebo-controlled trials (phase 2b ALIENTO and phase 3 ARNASA), current or former smokers with COPD and a history of frequent exacerbations, irrespective of baseline blood eosinophils, were randomly assigned (1:1:1; stratification by smoking status and region) to receive subcutaneous astegolimab 476 mg every 2 weeks, every 4 weeks, or placebo, alongside optimised inhaled maintenance therapy over 52 weeks. The primary endpoint (analysed in participants receiving one or more doses) was annualised rate of moderate or severe exacerbations. Missing data were considered similar to data from other participants in the same treatment group with the same baseline characteristics. The trials were registered with ClinicalTrials.gov (NCT05037929 and NCT05595642). FINDINGS: In ALIENTO, 1301 participants (astegolimab every 2 weeks, n=433; astegolimab every 4 weeks, n=437; and placebo, n=431) initiated treatment between Oct 5, 2021, and Feb 19, 2024. In ARNASA, 1375 participants (astegolimab every 2 weeks, n=459; astegolimab every 4 weeks, n=459; and placebo, n=457) initiated treatment between Jan 9, 2023, and June 25, 2024. Adjusted rate ratios versus placebo for the primary endpoint were 0·85 (95% CI 0·72-1·00; p=0·049) for astegolimab every 2 weeks and 0·93 (0·79-1·10; p=0·38) for astegolimab every 4 weeks in ALIENTO, and 0·85 (0·72-1·01; p=0·068) for astegolimab every 2 weeks and 0·82 (0·70-0·98; p=0·024) for astegolimab every 4 weeks in ARNASA. Adverse events were balanced between treatments, with most participants experiencing one or more adverse events (1093 [84·0%] of 1301 participants in ALIENTO and 1176 [85·5%] of 1375 in ARNASA). The most common non-COPD adverse event was nasopharyngitis in ALIENTO and upper respiratory chest infection in ARNASA. Deaths occurred in 40 (3·1%) of 1301 participants in ALIENTO and in 44 (3·2%) of 1375 participants in ARNASA, and were balanced across treatment groups. Across both trials, a total of three deaths (0·1%) were considered to be related to treatment by investigators. INTERPRETATION: In ALIENTO, astegolimab every 2 weeks was associated with a lower annual rate of exacerbations versus placebo in patients with COPD and a history of frequent exacerbations. In ARNASA, these findings did not meet statistical significance. Together, these findings suggest a role for targeting the ST2/IL-33 pathway to reduce the frequency of COPD exacerbations in patients with limited treatment options. FUNDING: Genentech, a member of the Roche Group, and F Hoffmann-La Roche.

References

1. 1.Papi, A., Greening, N. J., Bhatt, S. P., Roche, N., Celli, B., Wedzicha, J. A., Agustí, À., Tal-Singer, R., Han, M. K., Janssens, W., Hanania, N. A., Nair, P., Bremner, P., Porpodis, K., Shibata, Y., Korn, S., Yang, T., Gordon, O., Saenz, R., Ng, J., Cheung, D. S., Devine, J., Grimbaldeston, M. A., Zhang, W., Yang, X., Mohan, D., Vogelmeier, C. F., & Brightling, C. E. (2026). Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. *Lancet*, Article 10.1016/S0140-6736(26)00637-9. https://doi.org/10.1016/S0140-6736(26)00637-9